Inhibition of Transplantation Rejection By Suppressing HVEM

Decoy lymphotoxin beta receptor (LT? has potent immune inhibitory activities, and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LT?T?and LIGHT-HVEM/LT? underlying molecular mechanisms have yet to be fully understood. Scientists at JHU have now determined that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.

Inventor(s): Chen, Lieping

Type of Offer: Licensing



« More Medical Patents

---